Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

It is generally accepted that MHC II molecules confer susceptibility to inflammatory diseases because of the different abilities they possess for binding and presenting peptides to T cells. A new study suggests that the level of MHC II gene expression is also a risk factor for such diseases. It shows that a polymorphism in the promoter of the MHC II transactivator (MHC2TA) gene (which encodes CIITA), leads to reduced MHC2TA expression, and hence reduced production of MHC II molecules. This predisposes to rheumatoid arthritis, multiple sclerosis and myocardial infarction.

Original publication

DOI

10.1016/j.it.2005.08.011

Type

Journal article

Journal

Trends Immunol

Publication Date

11/2005

Volume

26

Pages

559 - 561

Keywords

Arthritis, Rheumatoid, Gene Expression Regulation, Histocompatibility Antigens Class II, Humans, Inflammation, Multiple Sclerosis, Myocardial Infarction, Polymorphism, Genetic, Promoter Regions, Genetic